Andrew Leask

Dr. Andrew Leask is a Professor at the University of Saskatchewan, based at the Health Sciences Building in Saskatoon. He holds a BSc in Cell Biology from the University of British Columbia and a PhD in Molecular Genetics and Cell Biology from the University of Chicago. As a leading researcher in matrix biology, he investigates fibrosis, tumor microenvironments, and matricellular protein dynamics, with implications for scleroderma, melanoma, and connective tissue disorders.

His research integrates molecular genetics, cell biology, and murine disease models to explore:

• Fibroblast plasticity in fibrotic and cancerous tissues
• CCN protein functions in cellular communication
• Therapeutic targeting of persistent fibrotic phenotypes
• Tumor neovascularization mechanisms

Analysis of his recent publications (2018-2021) reveals consistent focus on:

• CCN1/CCN2 roles in skin fibrosis and cancer-associated fibroblast activation
• Verteporfin as a potential antifibrotic agent
• Murine models of melanoma and scleroderma

Dr. Leask holds key editorial positions:

• Managing Editor, Journal of Cell Communication (instrumental in securing its first impact factor)
• Editorial Board, American Journal of Pathology

He also serves on scientific boards for the American Society of Matrix Biology and International CCN Society.

His laboratory has trained researchers now positioned at institutions including University of Toronto, Queen's University, and Genentech. While no lab name or website is specified, his group actively investigates fibroblast pathophysiology.